{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:32:21Z","timestamp":1785367941491,"version":"3.55.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["NNF20OC0060657"],"award-info":[{"award-number":["NNF20OC0060657"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Inhaled corticosteroids (ICSs) are associated with an increased risk of pneumonia among patients with chronic obstructive pulmonary disease (COPD). The introduction of extrafine particle ICS has aimed to improve the distribution of medicine in the airways by altering deposition within the lungs, potentially affecting efficacy and side effects. It remains unclear if extrafine particle ICS administration alters the risk of pneumonia compared with standard particle size ICS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational cohort study including all Danish COPD outpatients receiving ICS from 2010 to 2017. The primary outcome was pneumonia hospitalisation in the different ICS particle dosing regimens. The primary analysis was an adjusted Cox proportional hazards model. For sensitivity analysis, a subgroup analysis of patients receiving spray devices was done. Further, we created a propensity score matched cohort, in which we matched for the same covariates as adjusted for in the main analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 35\u2009691 patients were included of whom 1471 received extrafine particle ICS. Among these patients, 4657 were hospitalised due to pneumonia. Patients with COPD receiving extrafine particle ICS had a lower risk of hospitalisation due to pneumonia compared with patients receiving standard particle size ICS in our primary analysis (HR 0.75; 95% CI 0.63 to 0.89; p=0.002), subgroup analysis (HR 0.54; 95% CI 0.45 to 0.65; p&lt;0.0001) and the propensity-matched population (HR 0.72; 95% CI 0.60 to 0.87; p=0.0006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>The use of extrafine particle ICS administration was associated with a lower risk of pneumonia hospitalisation in patients with COPD compared with those who received standard size treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001814","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:20:43Z","timestamp":1695961243000},"page":"e001814","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-3235","authenticated-orcid":false,"given":"Christian Kjer","family":"Heerfordt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-4983","authenticated-orcid":false,"given":"Christian","family":"R\u00f8nn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitta Barrella","family":"Harboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truls Sylvan","family":"Ingebrigtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Svorre Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Torgny","family":"Wilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-347X","authenticated-orcid":false,"given":"Barbara","family":"Bonnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Biering-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Gitz","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theis Skovsgaard","family":"Itenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Krogh","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Ekl\u00f6f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrik St\u00e6hr","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2023092821201370000_10.1.e001814.1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.517"},{"key":"2023092821201370000_10.1.e001814.2","doi-asserted-by":"crossref","unstructured":"Kew KM , Seniukovich A , Cochrane Airways Group . n.d. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev;2014. doi:10.1002\/14651858.CD010115.pub2","DOI":"10.1002\/14651858.CD010115.pub2"},{"key":"2023092821201370000_10.1.e001814.3","doi-asserted-by":"crossref","unstructured":"Miravitlles M , Auladell-Rispau A , Monteagudo M , et al . Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev 2021;30:210075. doi:10.1183\/16000617.0075-2021","DOI":"10.1183\/16000617.0075-2021"},{"key":"2023092821201370000_10.1.e001814.4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cmi.2022.11.029","article-title":"Hospitalization for chronic obstructive pulmonary disease and pneumonia: association with the dose of inhaled corticosteroids. A nation-wide cohort study of 52 100 outpatients","volume":"29","author":"R\u00f8nn","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2023092821201370000_10.1.e001814.5","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S175047"},{"key":"2023092821201370000_10.1.e001814.6","doi-asserted-by":"crossref","unstructured":"El Baou C , DiSantostefano RL , Alfonso-Cristancho R , et al . Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med 2017;17:172. doi:10.1186\/s12890-017-0507-2","DOI":"10.1186\/s12890-017-0507-2"},{"key":"2023092821201370000_10.1.e001814.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1414OC"},{"key":"2023092821201370000_10.1.e001814.8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/jamp.2017.1396","article-title":"Harmonizing the nomenclature for therapeutic aerosol particle size: A proposal","volume":"31","author":"Hillyer","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2023092821201370000_10.1.e001814.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12061346"},{"key":"2023092821201370000_10.1.e001814.10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.nano.2015.01.007","article-title":"Inhalable Nanoparticulate powders for respiratory delivery","volume":"11","author":"Muralidharan","year":"2015","journal-title":"Nanomedicine"},{"key":"2023092821201370000_10.1.e001814.11","doi-asserted-by":"crossref","unstructured":"Sonnappa S , Martin R , Israel E , et al . Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One 2017;12:e0178112. doi:10.1371\/journal.pone.0178112","DOI":"10.1371\/journal.pone.0178112"},{"key":"2023092821201370000_10.1.e001814.12","unstructured":"Study protocol: inhaled corticosteroids particle size influence on risk of acquiring pneumonia for patients with chronic obstructive pulmonary disease. A populations-based cohort study. n.d. Available: http:\/\/coptrin.dk\/wp-content\/uploads\/2022\/08\/Protokol-ICS-Particle-Size-Pneumonia-Risk-COPD-18.08.2022.pdf"},{"key":"2023092821201370000_10.1.e001814.13","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99489"},{"key":"2023092821201370000_10.1.e001814.14","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811401482"},{"key":"2023092821201370000_10.1.e001814.15"},{"key":"2023092821201370000_10.1.e001814.16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6004"},{"key":"2023092821201370000_10.1.e001814.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0694OC"},{"key":"2023092821201370000_10.1.e001814.18","first-page":"1163","article-title":"Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD","volume":"9","author":"Postma","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2023092821201370000_10.1.e001814.19","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.2147\/COPD.S281333","article-title":"Clinical and economic consequences of inhaled corticosteroid doses and particle size in triple inhalation therapy for COPD: real-life study","volume":"15","author":"Sicras-Mainar","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2023092821201370000_10.1.e001814.20","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268807008564"},{"key":"2023092821201370000_10.1.e001814.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202872"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:21:14Z","timestamp":1695961274000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bmjresp-2023-001814"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001814","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}